Symbicort 160 mikrograma/ 4,5 mikrograma po potisku, stlačeni inhalat, suspenzija
| Name | Symbicort 160 mikrograma/ 4,5 mikrograma po potisku, stlačeni inhalat, suspenzija |
|---|---|
| Marketing Authorisation Number | HR-H-446429052 |
| Active Substance | budezonid formoterolfumarat dihidrat |
| Composition | jedna doza po potisku sadrži: 160 mikrograma budezonida po potisku i 4,5 mikrograma formoterolfumarat dihidrata po potisku |
| Pharmaceutical Form | stlačeni inhalat, suspenzija |
| Manufacturer | AstraZeneca Dunkerque Production, Dunkerque, Francuska |
| Marketing Authorisation Holder | AstraZeneca d.o.o., Ulica Vjekoslava Heinzela 70, Zagreb, Hrvatska |
| Marketing Authorisation Date | 26.01.2021 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/20-02/44 |
| Registration Number | 381-12-01/30-21-03 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | R03AK07 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |
